Age, years
| |
≥42
|
93 (55.7)
|
<42
|
74 (44.3)
|
Squamous cell carcinoma antigen, ng/ml
|
≤1.5
|
97 (58.1)
|
>1.5
|
51 (30.5)
|
No test
|
19 (11.4)
|
FIGO stage
| |
Ib1
|
68 (40.7)
|
Ib2
|
59 (35.3)
|
IIa1
|
38 (22.8)
|
IIa2
|
2 (1.2)
|
Tumour size, cm
| |
<4
|
106 (63.5)
|
≥4
|
61 (36.5)
|
Histological type
| |
Squamous cell carcinoma
|
153 (91.6)
|
Adeno cell carcinoma
|
14 (8.4)
|
Histological differentiation
| |
Well
|
8 (4.8)
|
Moderate
|
66 (39.5)
|
Poor
|
93 (55.7)
|
Deep stromal invasion
| |
No
|
67 (40.1)
|
Yes
|
100 (59.9)
|
Lymphovascular space involvement
| |
No
|
160 (95.8)
|
Yes
|
7 (4.2)
|
Positive parametrium
| |
No
|
162 (97)
|
Yes
|
5 (2.4)
|
Positive surgical margin
| |
No
|
164 (98.2)
|
Yes
|
3 (1.8)
|
Vaginal involvement
| |
No
|
157 (94.0)
|
Yes
|
10 (6.0)
|
T classification
| |
T1b1
|
113 (67.7)
|
T1b2
|
39 (23.4)
|
T2a
|
9 (5.4)
|
T2b
|
4 (2.4)
|
T4
|
2 (1.2)
|
N classification
| |
N0
|
140 (83.8)
|
N1
|
27 (16.2)
|
M classification
| |
No
|
160 (95.8)
|
Yes
|
7 (4.2)
|
Concurrent chemotherapy and radiotherapy
| |
No
|
59 (62.1)
|
Yes
|
36 (37.9)
|
Radiotherapy
| |
No
|
49 (68.1)
|
Yes
|
23 (31.9)
|
Recurrence
| |
No
|
148 (88.6)
|
Yes
|
19 (11.4)
|
Vital status (at follow-up)
| |
Alive
|
155 (92.8)
|
Dead
|
12 (7.2)
|
URG4 expression
| |
Low or no expression
|
108 (64.7)
|
High expression
|
59 (35.3)
|
0)
|